SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp. engages in the design, manufacture, and launch of rockets and spacecrafts. It provides satellite communication services. The company was founded by Elon Reeve Musk on March 14, 2002 and is headquartered in Hawthorne, CA.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is currently trending as investors debate the massive valuation of its record-breaking IPO, with the community split between long-term bullish optimism for space infrastructure and bearish warnings regarding overvaluation and potential liquidity risks. While some retail traders are aggressively accumulating shares to hold for the future, others are actively scouting for entry points below IPO levels, waiting for the initial hype and volatility to settle.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku is seeing high volatility and intense community speculation following a recent report that the company is exploring a potential sale to a major media entity. Investors are actively debating the viability of a buyout versus a standalone growth strategy, with many weighing the companys platform dominance and recent profitability against ongoing market skepticism and competitive pressures.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is seeing high volatility as capital rotates into the major SpaceX IPO, leading investors to debate whether this decline is a temporary liquidity shakeout or a broader sector de-rating. The community remains focused on upcoming launch catalysts and the stock's long-term competitive position versus Starlink, with many viewing the sharp price pullback as a potential buying opportunity.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is trending as investors digest the DOJ's approval of its high-stakes acquisition of Warner Bros. Discovery, while the community intensely debates the potential for a mid-July deal closure and the impact of looming antitrust challenges from several U.S. states. The conversation is heavily focused on whether this merger will serve as the necessary catalyst to drive the share price upward or if ongoing regulatory hurdles and debt concerns will continue to suppress valuation.

Entrepreneurshares Series Trust - ERShares Private-Public Crossover ETF

The ERShares Private-Public Crossover ETF (XOVR) is trending as investors debate its structure and valuation in relation to its significant exposure to SpaceX. While some community members are frustrated by the fund's recent price stagnation despite SpaceX's growth, others view it as an accessible, liquid entry point for pre-IPO space exposure compared to more volatile alternatives.

Tidal Trust II - Defiance Daily Target 2X Short ASTS ETF

ASTN is seeing significant volatility as traders leverage the ETF to play against the momentum of ASTS, which many investors view as a highly volatile meme stock. The community remains deeply divided, with bearish traders utilizing the 2X inverse ETF to bet on a correction while long-term bulls continue to debate the stock's valuation and potential for further gains.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF is seeing heavy community engagement driven by the recent NYSE uplisting of a major holding and speculation surrounding upcoming federal regulatory hearings. While investors are debating the impact of these developments on market makers and short-term price volatility, the conversation remains centered on a bullish long-term outlook and expectations for increased institutional participation.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk Corp (SNDK) is experiencing a parabolic rally driven by persistent AI-sector demand and institutional momentum, with the community actively debating whether the stock is in a sustainable growth phase or a speculative bubble. While some investors point to the stock's massive year-over-year gains and strong storage market fundamentals as justification for the run, many others are calling for a sharp correction, highlighting extreme RSI levels and the potential for a pullback as market liquidity shifts toward other major IPOs.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech 100 is experiencing significant volatility and downward pressure as investors rotate out of the fund to pursue direct exposure to the upcoming SpaceX IPO, which has triggered widespread selling despite the fund's heavy concentration in high-growth private tech assets. The community remains deeply divided, with some investors aggressively adding to positions on the belief that current market prices trade at a steep discount to the fund's true net asset value, while others are frustrated by management's dilution through share offerings and a lack of communication regarding the fund's underlying valuation.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is seeing strong community interest as positive clinical data for its subcutaneous Briumvi treatment fuels expectations for a potential buyout. Investors are closely monitoring management's commentary and institutional positioning, with many hopeful that upcoming industry conferences will further validate the stock's long-term growth trajectory.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimates

Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of -51.23% and -98.27%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue Estimates

Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +10.70% and +150.00%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates

Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +26.63% and +294.36%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy?

Bolt Biotherapeutics (BOLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Tops Revenue Estimates

Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +30.31% and +73.46%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Surpass Estimates

ANI (ANIP) delivered earnings and revenue surprises of +30.43% and +12.22%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of -3.95% and +8.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates

Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.

BOLTBolt Biotherapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BOLT News